Genzyme, a Sanofi company, has appointed William “Bill” Sibold as head of Multiple Sclerosis and Rogério Vivaldi as head of Rare Diseases. Both will join the Genzyme executive team and report to David Meeker. The MS and Rare Disease businesses are Genzyme’s core focus areas following its integration with Sanofi. “These appointments are a critical step in launching the new Genzyme,” said David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to pat...